Evidence map›Paper›PMID 40877158›Full record

ArticleIn vivo (Athens, Greece)

Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer.

Yoh-Ichiro Iwasa, Ryosuke Kitoh, Yoh Yokota, Kentaro Hori, Mariko Kasuga, Shintaro Yamazaki, Yutaka Takumi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoh-Ichiro IwasaDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan iwasa@shinshu-u.ac.jp.
Ryosuke KitohDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Yoh YokotaDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Kentaro HoriDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Mariko KasugaDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Shintaro YamazakiDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Yutaka TakumiDepartment of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThis study aimed to explore the long-term outcomes of patients with recurrent/metastatic head and neck cancer (RM-HNC) treated with nivolumab in a real-world setting. PATIENTS AND

methodsWe retrospectively analyzed 53 patients with R/M-HNC treated with nivolumab between 2017 and 2024 at the Shinshu University Hospital. Clinical data included response rates, overall survival (OS), progression-free survival 1 (PFS1) 1, PFS2, and immune-related adverse events (irAEs).

resultsThe median OS was 18.1 months, with 1-year, 2-year, and 4-year survival rates of 57.7%, 37.9%, and 23.3%, respectively. Mixed response (MR) was observed in 17% of patients, and these patients showed significantly better OS than those with progressive disease (

conclusionThis study provides new insights into the long-term efficacy of nivolumab in R/M-HNC, highlighting the favorable prognosis in NPC and in patients outside the CheckMate 141 criteria. Importantly, this study is the first to report the frequency of MR in HNC, with MR being associated with a significantly better prognosis.

Indexed as

Antineoplastic Agents, ImmunologicalHead and Neck NeoplasmsNivolumabAdultAgedFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNivolumabhead and neck cancerimmune checkpoint InhibitorNivolumabprogrammed cell death-1 (PD-1)

Identifiers

PMID40877158
PMCPMC12396057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.